Paul Feuerstadt, MD

Paul Feuerstadt, MD, FACG, AGAF, offers a glimpse of patients dealing with this and insights on improving patients’ quality of life, post-treatment with fecal microbiota, live-jslm (Rebyota [RBL]).

Paul Feuerstadt, MD, discusses the safe and effective use of RBL in preventing C difficile recurrence with positive physician feedback and high patient benefit

Phase 3 data link gut microbiome shifts to better mental health outcomes in patients treated with fecal microbiota, live-jslm.

To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.

Members of the panel discuss when and where they tend to utilize fecal microbiota transplantation for recurrent C. difficile infections in clinical practice.

Experts on the treatment of patients with C. difficile infections provide insights on the implementation of fecal microbiota transplant products into clinical practices.

The panel provides insights on common adverse effects associated with fecal microbiota transplantation and analyzes the possibility of FMT products carrying pathogens or food-borne allergens.

Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).

Sahil Khanna, MBBS, MS, discusses the effectiveness of live-JSLM (RBL) in preventing the recurrence of C. difficile infections.

Matthew D. Sims, MD, PhD, FACP, FIDSA, discusses how fecal microbiota transplantation therapies are administered and shares his clinical experience.

Carl V. Crawford, MD, provides a comprehensive overview of the two FDA-approved FMT therapies for patients with recurrent C. difficile infections.

The panel review data from foundational studies on fecal microbiota transplantation in patients with C. difficile infections.

A panel of experts on C. difficile infections discusses risks associated with antibiotic use, including vancomycin-resistant enterococci infections.

Focusing on the treatment of patients with C. difficile infections, Carl V. Crawford, MD, provides clinical insights on medication tapering practices and therapies being utilized by clinicians.

Matthew D. Sims, MD, PhD, FACP, FIDSA, discuss how antibiotics do not completely eliminate C. difficile infections, the drivers of recurrence, and new treatments that are addressing eubiosis and C. difficile spores.

Experts on C. difficile infections give an overview of the ACG and IDSA/SHEA treatment guidelines for initial infection, first recurrence, and subsequent recurrences.

Paul Feuerstadt, MD, FACG, AGAF, provides clinical insights on diagnostic testing practices for C. difficile infections, highlighting the EIA, GDH, and PCR assays.

Sahil Khanna, MBBS, MS, outlines patients at risk for recurrent C. difficile infections, and Teena Chopra, MD, MPH, FACP, FIDSA, FSHEA, focuses on environmental considerations that can help prevent transmission.

Carl V. Crawford, MD, outlines the risk factors for C. difficile infections, focusing on factors that affect the body’s microbiome or immune system, including antibiotics, age, comorbid conditions, exposures, and prior C. difficile infections.

Teena Chopra, MD, MPH, FACP, FIDSA, FSHEA, and Matthew D. Sims, MD, PhD, FACP, FIDSA, provide clinical insights on the rate of recurrence of C. difficile infections and the impact on patients.

A panel of experts provide an overview of the epidemiology of Clostridioides difficile infections, highlighting diagnostic practices and the role of antimicrobial stewardship.

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.

Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).

Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.